F194. ASSOCIATION STUDY BETWEEN TREATMENT RESPONSE OF AMISULPRIDE AND DOPAMINE D3 RECEPTOR GENE POLYMORPHISMS. (1st April 2018)

• Record Type: Journal Article
• Authors: Lee, Kwanghun; Bahk, Won-Myong; Yoon, Bo-Hyun; Jon, Duk-In; Lee, Sang-Yeol; Kim, Moon Doo; Nam, Beomwoo; Song, Min-Kyu
• Is Part Of: Schizophrenia bulletin. Volume 44(2018)Supplement 1
• Page Start: S296
• Page End: S296
• Publication Date: 2018-04-01
• Subjects: Schizophrenia -- Periodicals; Schizophrenia -- Research -- Periodicals; 616.898005
• DOI: 10.1093/schbul/sby017.725
• Languages: English
• ISSNs: 0586-7614

Abstract

Abstract: Background: The aim of this study is to evaluate the association between rs6280 and rs905568 genetic polymorphism of DRD3 gene and the treatment response of amisulpride. Methods: After six weeks treatment of amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S). The genotyping for rs6280 and rs905568 was performed using TaqMan single nucleotide polymorphism (SNP) genotyping assay. Results: There was no significant difference in the frequency of genotype and allele of rs6280 between the responders and non-responders based on the total, positive, and general score of PANSS and CGI-S score. However, there was a significant association between this SNP and treatment response in the negative score of PANSS (χ2 = 5.23, p = 0.022). There was no significant association between rs905568 and the response in positive, negative, general, and total PANSS score and CGI-S score. Discussion: This is the first positive association study between DRD3 gene and the treatment response of negative symptoms to amisulpride in Korean schizophrenia patients. A larger scale research on more SNP of the DRD3 gene will make a progress in the study of pharmacogenetics on the treatment response of the amisulpride.